A critical appraisal of the functional evolution of P2Y12 antagonists as antiplatelet drugs

S. M A Fayaz, G. K. Rajanikant

Research output: Contribution to journalReview article

Abstract

P2Y12 receptor mediated inhibition of platelet aggregation is one of the most explored and exploited pathways in antiplatelet drug therapy to prevent ischemic events in patients undergoing percutaneous coronary intervention (PCI) for the treatment of the acute coronary syndrome (ACS). Ticlopidine, Clopidogrel, Prasugrel, Ticagrelor, Cangrelor and Elinogrel are the P2Y12 inhibitors that act as antiplatelet drugs. In this review, the features of these drugs and the factors reported to be responsible for drug resistance or drug ineffectiveness were described. The features like drug metabolism, reversible or irreversible binding of drugs to their target protein and the mode of administration were observed to evolve along with the antiplatelet drugs. These features also include the drug-drug interactions, the pharmacogenetics and pharmacodynamics of P2Y12 inhibitors. We attempted to critically analyze how the desirable features were met by the P2Y12 inhibitors in the course of time. This review provides an overview of the evolution of P2Y12 inhibitors and may guide the researchers to develop better antiplatelet drugs in the future.

Original languageEnglish
Pages (from-to)1625-1634
Number of pages10
JournalCurrent Pharmaceutical Design
Volume18
Issue number12
DOIs
Publication statusPublished - 01-04-2012

Fingerprint

Platelet Aggregation Inhibitors
Pharmaceutical Preparations
clopidogrel
Ticlopidine
Pharmacogenetics
Percutaneous Coronary Intervention
Acute Coronary Syndrome
Drug Interactions
Platelet Aggregation
Drug Resistance
Research Personnel
Drug Therapy
Proteins

All Science Journal Classification (ASJC) codes

  • Drug Discovery
  • Pharmacology

Cite this

@article{8f1a1deede0b40c9b710a70ee70c0641,
title = "A critical appraisal of the functional evolution of P2Y12 antagonists as antiplatelet drugs",
abstract = "P2Y12 receptor mediated inhibition of platelet aggregation is one of the most explored and exploited pathways in antiplatelet drug therapy to prevent ischemic events in patients undergoing percutaneous coronary intervention (PCI) for the treatment of the acute coronary syndrome (ACS). Ticlopidine, Clopidogrel, Prasugrel, Ticagrelor, Cangrelor and Elinogrel are the P2Y12 inhibitors that act as antiplatelet drugs. In this review, the features of these drugs and the factors reported to be responsible for drug resistance or drug ineffectiveness were described. The features like drug metabolism, reversible or irreversible binding of drugs to their target protein and the mode of administration were observed to evolve along with the antiplatelet drugs. These features also include the drug-drug interactions, the pharmacogenetics and pharmacodynamics of P2Y12 inhibitors. We attempted to critically analyze how the desirable features were met by the P2Y12 inhibitors in the course of time. This review provides an overview of the evolution of P2Y12 inhibitors and may guide the researchers to develop better antiplatelet drugs in the future.",
author = "Fayaz, {S. M A} and Rajanikant, {G. K.}",
year = "2012",
month = "4",
day = "1",
doi = "10.2174/138161212799958558",
language = "English",
volume = "18",
pages = "1625--1634",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "12",

}

A critical appraisal of the functional evolution of P2Y12 antagonists as antiplatelet drugs. / Fayaz, S. M A; Rajanikant, G. K.

In: Current Pharmaceutical Design, Vol. 18, No. 12, 01.04.2012, p. 1625-1634.

Research output: Contribution to journalReview article

TY - JOUR

T1 - A critical appraisal of the functional evolution of P2Y12 antagonists as antiplatelet drugs

AU - Fayaz, S. M A

AU - Rajanikant, G. K.

PY - 2012/4/1

Y1 - 2012/4/1

N2 - P2Y12 receptor mediated inhibition of platelet aggregation is one of the most explored and exploited pathways in antiplatelet drug therapy to prevent ischemic events in patients undergoing percutaneous coronary intervention (PCI) for the treatment of the acute coronary syndrome (ACS). Ticlopidine, Clopidogrel, Prasugrel, Ticagrelor, Cangrelor and Elinogrel are the P2Y12 inhibitors that act as antiplatelet drugs. In this review, the features of these drugs and the factors reported to be responsible for drug resistance or drug ineffectiveness were described. The features like drug metabolism, reversible or irreversible binding of drugs to their target protein and the mode of administration were observed to evolve along with the antiplatelet drugs. These features also include the drug-drug interactions, the pharmacogenetics and pharmacodynamics of P2Y12 inhibitors. We attempted to critically analyze how the desirable features were met by the P2Y12 inhibitors in the course of time. This review provides an overview of the evolution of P2Y12 inhibitors and may guide the researchers to develop better antiplatelet drugs in the future.

AB - P2Y12 receptor mediated inhibition of platelet aggregation is one of the most explored and exploited pathways in antiplatelet drug therapy to prevent ischemic events in patients undergoing percutaneous coronary intervention (PCI) for the treatment of the acute coronary syndrome (ACS). Ticlopidine, Clopidogrel, Prasugrel, Ticagrelor, Cangrelor and Elinogrel are the P2Y12 inhibitors that act as antiplatelet drugs. In this review, the features of these drugs and the factors reported to be responsible for drug resistance or drug ineffectiveness were described. The features like drug metabolism, reversible or irreversible binding of drugs to their target protein and the mode of administration were observed to evolve along with the antiplatelet drugs. These features also include the drug-drug interactions, the pharmacogenetics and pharmacodynamics of P2Y12 inhibitors. We attempted to critically analyze how the desirable features were met by the P2Y12 inhibitors in the course of time. This review provides an overview of the evolution of P2Y12 inhibitors and may guide the researchers to develop better antiplatelet drugs in the future.

UR - http://www.scopus.com/inward/record.url?scp=84860183727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860183727&partnerID=8YFLogxK

U2 - 10.2174/138161212799958558

DO - 10.2174/138161212799958558

M3 - Review article

C2 - 22360514

AN - SCOPUS:84860183727

VL - 18

SP - 1625

EP - 1634

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 12

ER -